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Bradykinin is a mediator of anaphylactoid reactions during hemodial-
ysis with AN69 membranes. Anaphylactoid reactions (AR) are the most
feared complications of hemodialysis. Recently, a high incidence of AR
has been reported during dialysis with AN69 membranes in patients
treated with ACE inhibitors. Plasma levels of C3a, histamine and
bradykinin were measured in 12 patients at the onset of AR during
dialysis with AN69. We also investigated bradykinin generation in 10
symptom-free patients dialyzed with four different membranes. None of
the 12 patients studied during AR displayed excessive complement
activation or histamine release. In contrast, high bradykinin plasma
levels (2392 53 fmollml; mean SEM) were observed in all nine
patients of whom bradykinin was measured. One patient developed two
consecutive episodes of hypersensitivity on AN69 membranes even
without taking ACE inhibitors. Bradykinin levels were high in both
episodes (5280 and 10467.7 fmollml). Furthermore, this patient showed
no symptoms and normal bradykinin levels (123.4 fmol/ml) when
dialyzed with other membranes. The role of the membrane type in the
AR is further substantiated by the observation that AN69 also provoked
a signifIcantly higher bradykinin generation (327.6 18 fmol/ml; mean
SEM) during symptom-free sessions compared to other membranes
like CuprophanE (5.1 7.3), HemophanR (17.2 6.3) and PolysulfoneR
(39.7 6.6). Our findings strongly suggest that bradykinin is the
principal mediator of AR during hemodialysis with AN69 membranes.
To our knowledge it is the first time that data support the hypothesis of
a more general role of bradykinin in shock-like symptoms. Further-
more, bradykinin generation must be regarded as a new marker of
biocompatibility of extracorporeal treatments.
Exposure of blood to the extracorporeal circuit during hemo-
dialysis may initiate a number of adverse reactions of which the
life-threatening anaphylactoid reaction is the most feared one.
Although the etiology of these reactions remains controversial,
it is generally accepted that in many cases ethylene oxide
hypersensitivity may have induced these anaphylactoid reac-
tions [1]. Other etiological factors claimed to contribute to these
reactions are complement activation [21 and passage of bacterial
products across high permeable dialysis membranes [3—7].
Recently, a new mechanism of severe anaphylactoid reac-
tions has been proposed to occur during hemodialysis with the
synthetic AN69 polyacrylonitrile membrane [6—101. Most of the
reactions were observed in patients treated with angiotensin
converting enzyme (ACE) inhibitors, though a few episodes
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have also been reported independent of ACE inhibition [91. The
pathogenesis of these anaphylactoid reactions is not elucidated,
but the seeming involvement of ACE inhibitors in the vast
majority of cases suggests a role for bradykinin. Bradykinin is
generated via contact activation and thus, contact of blood with
negative charges [11, 121 on the surface of AN69 membrane
could cause release of bradykinin. Normally, the released
bradykinin is effectively degraded by the action of angiotensin
converting enzyme (which is identical to kininase II), but in the
presence of an ACE inhibitor the degradation is inhibited and
bradykinin can accumulate [13].
The purpose of the present study was to investigate whether
the "bradykinin hypothesis" might be correct, first by evaluat-
ing plasma levels of C3a, histamine and bradykinin in patients
who had shown severe clinical reactions during hemodialysis
with AN69 membranes and then by additional, more indirect
experiments.
Methods
Clinical studies
Anaphylactoid reactions were defined as a symptomatic
blood pressure drop (nausea and faintness), flushing, swelling of
tongue and/or throat, metallic taste, and paresthesiae in the
extremities. Severe hypotension was defined as a systolic blood
pressure drop of 50 mm Hg or more.
Study 1. From January 31, 1990 to April 30, 1990, 86 patients
who required chronic hemodialysis were treated with an AN69
polyacrylonitrile parallel-plate dialyzer and with a dialysis
solution containing acetate. The dialyzers were reprocessed
with 0.45% (62.5 mmol/liter) sodium hypochiorite and reused
five times. The dialyzers were reprocessed on a non-commer-
cial microprocessor controlled unit which cleans five dialyzers
at a time. It first rinses the blood compartment with reverse
osmosis water at 2 liter/mm for 10 minutes and the dialysate
compartment by ultrafiltration, then flushes 0.45% sodium
hypochlorite through both compartments at 300 mllmin for five
minutes. After cleaning they were filled with 0.45% sodium
hypochlorite and stored. Before reuse, the dialyzers were
rinsed with a saline solution until negative (<1 ppm) for residual
hypochlorite by a solution containing potassium iodate (20 g
starch, 12.5 g potassium iodate, 1 g benzylalcohol, aqua ad 1
liter).
During this period 12 patients were treated with ACE inhib-
itors. All of them developed one episode of anaphylactoid
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reaction at the onset of hemodialysis on AN69. These 12
episodes of anaphylactoid reactions occurred during 28 hemo-
dialysis sessions on AN69 in patients receiving ACE inhibitors.
Thus, not during every "at risk" dialysis session was an
anaphylactoid reaction observed. The anaphylactoid reactions
resolved after discontinuation of ACE inhibitor therapy.
During the reactions blood samples were drawn into EDTA
from the arterial (before the dialyzer) and venous (after the
dialyzer) line. C3a and histamine were determined in these
samples as described below and compared with samples drawn
from 12 control patients without reactions but dialyzed on
AN69 and not taking ACE inhibitors five minutes after start of
dialysis (arterial line only).
Of only nine of the 12 patients showing reactions plasma from
the samples drawn from the arterial line was available to
measure bradykinin later on (June 1992). These samples were
compared with the arterial samples of nine control patients
without reactions but dialyzed on AN69 and not taking ACE
inhibitors. Thus, these control samples were also stored for two
years.
From ten of the 12 patients with anaphylactoid reactions the
dialysate was analyzed for endotoxin content and five of them
were also analyzed for the microbial count.
In all patients IgE antibodies against ethylene oxide were
determined.
However, since we learned later (June 1992) that the reliable
determination of bradykinin is normally done using a special
inhibitor cocktail to block proteolytic as well as kininase
activity (see below) we performed a control study. In this study
samples (arterial line only) from nine patients on AN69 without
reactions and not taking ACE inhibitors were drawn in parallel
into EDTA and into inhibitor cocktail.
Study 2. In this study we examined the possible involvement
of the dialysis membrane as a cause in the anaphylactoid
reactions. For ethical reasons it was impossible to study the
membrane effects with patients taking ACE-inhibitors. Since,
however, according to the bradykinin hypothesis (see introduc-
tion) the ACE inhibitors are not directly involved in bradykinin
generation but rather in bradykinin breakdown, we hypothe-
sized that membrane differences must be detectable also in
patients not taking ACE inhibitors. We therefore studied 10
asymptomatic patients in a prospective cross over trial using
four different dialysis membranes (first use) in a single dialysis
treatment. We used AN69 (Biospal 3000S; Hospal), Cuprophan
(GFE 18; Gambro), Hemophan (GFS Plus 16; Gambro) and
high flux polysulfone (F60; Fresenius). Five minutes after the
'tart of blood circulation and connection of the venous line to
ie patient, blood samples were drawn before and after the
dialyzer for measurement of the bradykinin plasma levels.
During the course of this study a 26-year-old woman (not
treated with ACE inhibitors) developed two episodes of ana-
phylactoid reaction three to five minutes after the start of
hemodialysis only with AN69 but not with Cuprophan and
Polysulfone. Ethylene oxide hypersensitivity was excluded by
RAST. Blood samples were collected five minutes after the
start of hemodialysis with AN69 (Biospal 3000S; Hospal),
Cuprophan (GFE 18; Gambro) and Polysulfone (F60; Frese-
nius).
All subjects gave informed consent.
Laboratory methods
Plasma bradykinin assay. Plasma sampling and processing
[14]. In study 1 blood was drawn into a syringe containing
EDTA (1.5 mg/ml K2EDTA) and centrifuged within 10 minutes
at 4°C. The plasma was stored at —70°C till analysis. Mter
thawing of plasma inhibitor cocktail was added (1:9 vollvol).
Two hundred microliters of this mixture were added to 800 d
ice cold ethanol and allowed to stand for 15 minutes at 4°C.
Then the mixture was boiled for 15 minutes to 70°C. After
centrifugation the supernatant was evaporated to dryness under
a stream of air.
In study 2, 900 tl of blood were collected into ice-cooled
polypropylene tubes containing 100 jd inhibitor cocktail, mixed
gently, cooled at 4°C and centrifuged within 15 minutes at 4°C.
The inhibitor cocktail contained 10,000 KIU/ml aprotinin, 800
pg/ml soybean trypsin inhibitor, 4 mg/ml polybrene, 10 mg/mI
1,10 phenantroline and 20 mg/mI EDTA. Two hundred micro-
liters plasma were added to 800 d ice cold ethanol and allowed
to stand for 15 minutes at 4°C. After centrifugation the super-
natant was separated and evaporated under a stream of air. The
dried residue was redissolved in 600 d 66% acetone/water and
washed with 1.4 ml petrol ether. After centrifugation at room
temperature the upper layer was aspirated and discarded. The
lower layer was evaporated under a stream of air.
Determination of kinins by radioimmunoassay. Buffer A. 0.01
M NaH2PO4, 0.14 M NaCI, 0.03 M EDTA, 3 mri 1,10-phenantro-
line, 0.5 g/liter NaN3, 0.2 g/liter thimerosal, 0.4 mllliter of
Tween 20, pH 7.4.
Buffer B. Same as buffer A but containing polyethyleneglycol
6000, 60 g/liter instead of Tween 20.
Buffer C. Same as buffer A but containing ovalbumin, 10
g/liter instead of Tween 20.
Radioiodination. Tyrosyl-bradykinin was labeled with io-
dine-125 in a similar way as described by Shimamoto et al [15],
diluted in buffer A to a concentration of 500,000 counts/min/ml
and 70 mg/liter of rabbit immunoglobulin G were added.
Radioimmunoassay procedure. Standard dilutions of brady-
kinin (15,6 to 8000 pmol/liter) were prepared with buffer A.
Antibody to kinin was provided by Dr. K. Shimamoto (Sap-
poro, Japan). The lyophilized antiserum was reconstituted in
buffer C and diluted in buffer A to give a binding of the labeled
antigen of 30 to 40% under the radioimmunoassay conditions.
The dried samples were dissolved in 0.4 ml buffer A. A 50 d
sample (standard or unknown), 50 j.d buffer A, 50 jd ofa freshly
prepared solution of the '251-tyrosyl-bradykinin and 50 jl of the
antiserum dilution were mixed in 600 /Ll RIA tubes (Sarstedt,
D-5223 NUmbrecht, Cat. No. 73.1055) and incubated for 16 to
24 hours at 4 to 10°C. Then 50 tl of the second antibody (diluted
1:32 according to the manufacturer recommendation) and 300 sl
buffer B were added. The samples were centrifuged at 4600 g for
20 minutes at 9°C. The supernatant was aspirated, 500 d buffer
B were added and after centrifugation and aspiration of the
supernatant the radioactivity of the precipitates was measured
in a gamma counter. The assays were evaluated by the spline
approximation method using the commercially available com-
puter program RIALOG II (Zinsser Analytic, Frankfurt Ger-
many).
Reproducibility of the RIA. The reproducibility of the assay is
determined routinely at concentration levels of 15, 180, and 750
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Table 1. Data of patients with anaphylactoid reactions during hemodialysis with AN69 membranes under ACE inhibition
Patient Treatment
Dialyzer
use no.
C3aa
A
ng/ml
V
Histam
A
inea aM
V
Endotoxin
EU/rn! CFU/ml
1 Enalapril 2 444.4 886.7 1.9 3.47 0.44 20
10 mg/day
2 Enalapril 4 154.4 166.1 1.9 1.8 1.19 2500
20 mg/day
3 Enalapril 4 262.7 NA 0.23 NA 0.28 21
2.5 mg/day
4 Enalapril 1 199.7 NA 2.57 NA 0.31 10
20 mg/day
5 Captopril 1 258.3 250.6 1.61 4.91 0.03 4
75 mg/day
6 Captopril 2 1140.5 517.5 6.0 0.37 1.13 NA
75 mg/day
7 Lisinopril 2 472.2 481.7 5.78 1.6 0.33 NA
20 mg/day
8 Enalapril 2 296.3 229 2.55 0.48 1.6 NA
20 mg/day
9 Enalapril I 805.9 359.8 1.79 1.9 0.09 NA
20 mg/day
10 Enalapril 2 668.7 502.1 5.91 1.34 0.14 NA
10 mg/day
11 Enalapril 1 340.3 392.9 1.42 1.88 NA NA
10 mg/day
12 Enalapril 6 869.4 617.5 0.07 0.68 NA NA
10 mg/day
Median 392.4 437.3 1.9 1.7 0.31
Mean 493.5 440.4 2.64 1.84 0.55
SEM 17.3 14.2 1.42 1.15 0.74
Abbreviations are: A, arterial line; V, venous line; NA, not available.
a NS between arterial and venous values
fmollml; the coefficients of variation at these levels are 18.7,
14.3 and 16.6%, respectively.
Plasma histamine assay
Five milliliters of blood were collected into an ice cooled tube
(Monoject) containing 7.2 mg K2EDTA and centrifuged within
10 minutes at 2000 g at 4°C; the plasma was stored at —70°C
until assayed. After thawing, the plasma samples were assayed
with a commercial radioimmunoassay for measurement of
histamine (Immunotech, AMAC Inc.)
Plasma C3a assay
Five milliliters of blood were collected into an ice cooled tube
(Monoject) containing 7.2 mg K2EDTA and centrifuged within
10 minutes at 2000 g at 4°C; the plasma was stored at —70°C
until assayed. After thawing, the plasma samples were assayed
with a commercial enzyme immuno assay for measurement of
C3a (Progen).
Analysis for IgE antibodies against ethylene oxide
IgE antibodies against ethylene oxide were measured by a
radio-allergo-sorbent-test (Pharmacia CAP System RAST
RIA).
Endotoxin measurement
Ten milliliters dialysate were sampled in endotoxin-free glass
tubes. This glassware was rendered endotoxin-free by heating
for four hours at 180°C. Prior to analysis the samples were
stored at —70°C. The Coatest Endotoxin method (KabiVitrum
Diagnostica) was used for the quantitative, photometric deter-
mination of gram-negative bacterial endotoxins.
Quantitative bacteriology of dialysis solution
One hundred milliliters of dialysis solution were collected
into a sterile container and treated by membrane filtration
technique (Millipore 0.45 s pore size). After filtration the
membrane filter was inoculated on Tryptone soy agar (Lab M).
After incubation at 37°C for 48 hours the number of colony
forming units (CFU) was determined.
Statistical analysis
Data were analyzed by means of the Student's t-test and
subsequent Tukey's Studentized range test (analysis of vari-
ance). As non-parametric test the Wilcoxon rank sum test was
used. Differences were considered significant when a P < 0.05
was obtained.
Results
Study I
In our first study we documented episodes of anaphylactoid
reaction in 12 patients within few minutes after the start of
dialysis (Table 1). All these patients were treated with ACE
inhibitors. Reactions were observed with first-used (patients 4,
5, 9 and 11) and re-used (patients 1, 2, 3, 6, 7, 8, 10 and 12)
AN69 dialyzers.
There was no statistically significant difference of the C3a
plasma level in the arterial line between the patients with
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Table 2. Symptoms and bradykinin plasma levels (arterial line; in
fmol/ml) at the onset of anaphylactoid reactions during concomitant
exposure to AN69 and ACE inhibition
Bradykinin
Patient Symptoms
plasma level
fmol/m/
1 flushing, swelling of tongue and throat,
nausea and paresthesiae
596
2 hypotension, flushing and abdominal
pain
NA
3 hypotension, flushing 8212
4 hypotension, flushing NA
5 hypotension, flushing, paresthesiae NA
6 flushing, metallic taste 880
7 flushing, nausea 660
8 hypotension, dyspnea, paresthesiae and
vulvodynia
6260
9 hypotension, flushing 1448
10 hypotension, flushing, swelling of
throat, nausea and abdominal pain
1968
11 flushing, nausea and abdominal pain 608
12 hypotension, flushing, dyspnea and
nausea
892
Median 1448
Mean 2392
SEM 53.3
Abbreviation is NA, not available.
reactions (493.4 17.3 ng/ml, Table 1) and control group 1
(458.9 16.9 ng/ml, individual data not shown). No significant
differences were observed between the C3a plasma levels from
the arterial and venous lines of both the cases and the controls.
There was no statistically significant difference of the hista-
mine plasma level in the arterial line between the patients with
reactions (2.64 1.42 nM) and control group 1(1.54 0.89 nM).
No significant difference has been observed between the hista-
mine plasma levels from the arterial and venous lines of both
the cases and the controls.
In ten episodes of anaphylactoid reactions, endotoxin content
was measured in the dialysate. The values ranged from 0.03 to
1.6 EU/mI (3 to 160 pglml). During five episodes dialysate was
sampled for the counting of colony-forming units (CFU). Only
once a high number (2,500 CFU/ml) was found but at the
occasion of the other reactions much smaller numbers were
measured (<21 CFU/ml).
Bradykinin plasma levels in the arterial line of the patients
during reactions (2392 53.3 fmol/ml; mean SEM; Table 2)
were found significantly higher compared to the controls of 1990
(350.3 15.9; Table 3). Since during the reactions we were not
aware of the correct sampling technique for bradykinin plasma
our data were validated later [19921 by comparing our technique
with an established one (Methods section, compare Table 3). In
this control study the use of an inhibitor cocktail (IC+) resulted
in about a fourfold lower bradykinin plasma level (62.7 7.9
fmol/ml) compared to sampling without inhibitor cocktail (250
15.1; IC—). We conclude that the absolute values of brady-
kinin plasma levels measured in blood samples obtained during
the reactions were likely to be too high but the differences
between case sessions and non-case sessions were valid and
indicative of bradykinin generation during the anaphylactoid
reactions, since the differences caused by inappropriate sam-
pling were much lower. The results of the 1990 control group
Table 3. Effect of the use of an inhibitor cocktail on bradykinin
plasma levels (arterial line; in fmol/ml) 5 minutes after the start of
hemodialysis on AN69 in patients without ACE inhibition
1990
IC—
1992
IC— IC+
198 568 0
543 324 92
116 44 44
174 68 52
580 64 32
278 144 44
856 280 72
160 92 0
248 664 208
Median 248 144 44
Mean 350 250 62.7
SEM 15.9 15.2 79
Abbreviations are: IC—, blood drawn without inhibitor cocktail;
IC+, blood drawn with inhibitor cocktail.
NS between IC— of 1990 and 1992.
P < 0.05 between IC— and IC+.
P < 0.01 between IC— of 1990 and bradykinin plasma levels of
patients showing anaphylactoid reactions (Table 2).
also demonstrate that the storage for two years and subsequent
sample treatment cannot be responsible for the high bradykinin
levels in the plasma of patients with anaphylactoid reactions as
the comparison with the 1992 IC— control group shows (Table
3). Interestingly, there is some correlation between the intensity
of elevation of bradykinin plasma levels and the degree of
symptomatology: patients without severe hypotension (patients
1, 6, 7, 11) had lower bradykinin plasma levels than patients
presenting with severe hypotension (Table 2).
None of the patients showed IgE antibodies against ethylene-
oxide.
Study 2
In a second study bradykinin plasma levels of 10 chronic
hemodialysis patients not taking ACE inhibitors were measured
in a cross over design before and five minutes after the start of
dialysis following the first-use of four different dialysis mem-
branes: AN69 (Biospal 3000S; Hospal), Cuprophan (GFE 18;
Gambro), Hemophan (GFS Plus 16; Gambro) and high flux
polysulfone (F60; Fresenius) (Table 4). Bradykinin plasma
levels in hemodialysis patients before dialysis ranged from 0 to
212 fmot1ml (26.5 28, mean SEM; data not shown). With the
use of polysulfone and AN69 an increase of the plasma brady-
kinin level in the arterial line was observed five minutes after
thestartofdialysis(9l.5 12.1 and6l.2 7.5). Onlywiththe
AN69 membrane was a significant bradykinin generation across
the dialyzer noted.
During our study, a 26-year-old woman who was not treated
with ACE inhibitors developed two episodes of anaphylactoid
reactions during two sessions on first-use AN69 membranes
(Biospal 3000S; Hospal). Bradykinin plasma levels were mea-
sured and compared to sessions remaining uneventful on Cu-
prophan (GFE 18; Gambro) and high-flux polysulfone mem-
branes (F60; Fresenius). The use of AN69, but not the other
two membranes, resulted in extremely high bradykinin plasma
levels both in the arterial and venous lines (Table 5).
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Table 4. Bradykinin plasma levels (fmol/ml) 5 minutes after the start of hemodialysis: Comparison between several membranes
Patient Cuprophan Hemophan Polysulfone AN69
No. A V A V A V A V
1 168 0 0 0 175 47.3 0 136
2 0 0 164 128 0 41.1 92 444
3 0 0 0 0 0 0 44 144
4 0 0 28 44 0 0 52 0
5 0 0 0 0 0 125.6 32 1212
6 0 0 56 0 24.4 18.6 44 328
7 0 0 0 0 0 0 72 340
8 0 0 44 0 211 64.2 0 56
9 0 0 0 0 469.7 100.6 68 252
10 0 46 0 0 34.7 0 208 364
Median 0 0 0 0 12.2 29.8 48 290
Mean 18.7 5.1 29.2 17.2 91.5 39.7 61.2 327.6
SEM 7.3 7.3 7 6.3 12.1 6.6 7.5 18
Abbreviations are: A, arterial line; V, venous line.
P < 0.05 for arterial/venous differences between AN69 and all other membranes.
Table 5. Bradykinin plasma levels (fmol/ml) at the onset of
anaphylactoid reactions during hemodialysis with AN69
0mm SminA SminV
AN69 (1st episode) 212 2112 5280
AN69 (2nd episode) 76.1 2106.6 10467.7
Cuprophan (one uneventful 0 36 0
treatment)
Polysulfone (one uneventful 28.7 0 123.4
treatment)
Abbreviations are: A, arterial line; V, venous line.
Discussion
Our patients with anaphylactoid reactions neither displayed a
IgE-mediated sensitization against ethylene-oxide, nor exces-
sive release of histamine or complement fragments during the
reactions. Therefore, these mechanisms are obviously not
involved in our cases. In contrast, the bradykinin plasma levels
of the patients were significantly elevated (Table 2). Though the
sample collection and sample treatment were different from
generally recommended procedures, we were able to exclude
that the bradykinin plasma levels were simply due to inappro-
priate sample handling but reflected, indeed, bradykinin gener-
ation during hemodialysis. Interestingly, some correlation
could be found between the intensity of elevation of bradykinin
plasma levels and the severity of anaphylactoid reaction; pa-
tients showing severe hypotension had higher bradykinin
plasma levels than patients who did not.
Two effects seem to be responsible for the bradykinin accu-
mulation observed: an increased release of bradykinin caused
by the AN69 membrane and a reduced breakdown of bradyki-
nm due to the inhibition of the ACE (=kininase II) by ACE
inhibitors. This hypothesis is supported by in vitro data indi-
cating that the accumulation of bradykinin formed via blood
contact with the AN69 membrane is strictly ACE inhibitor
dose-dependent [16].
Very high plasma levels of bradykinin at the onset of the
anaphylactoid reaction during hemodialysis with AN69 mem-
branes were observed in a 26-year-old patient who was not
treated with ACE inhibitors (Table 5). She remained symptom-
free and showed normal plasma levels of bradykinin during
hemodialysis with Cuprophan and high flux polysulfone. Impor-
tantly, in this setting a methodological flaw in the collection of
samples was excluded as blood was drawn into an inhibitor
cocktail. Therefore, these data strongly suggest that bradykinin
is the principal mediator of anaphylactoid reactions during
hemodialysis with AN69 membranes. On the other hand, this
case demonstrates that special properties of the AN69 mem-
brane must be responsible for the bradykinin release. However,
the development of an anaphylactoid reaction must in this case
also be due to an as yet unrecognized inability of the patient to
degrade bradykinin efficiently.
To further investigate the contributory role of AN69 in the
generation of bradykinin, we compared four different dialysis
membranes. Only during dialysis with AN69 membranes did we
observe a significant generation of bradykinin within the dia-
lyzer. The cause of bradykinin generation by AN69 membrane
can be understood by taking into account that the membrane
surface carries negatively charged groups [12]. These negative
groups may activate the Hageman factor which is known to
convert prekallikrein to kallikrein [12]. Kallikrein will release
bradykinin from high molecular weight kininogen. Despite a
significant generation of bradykinin within the AN69 dialyzer,
the bradykinin plasma levels in the arterial line remained rather
low. This can be explained by the pulmonary clearance of
bradykinin mediated by angiotensin converting enzyme activity
and which might be estimated to be 95 to 97% of the released
amount within the AN69 dialyzer [17].
Our in vivo data are supported by in vitro experiments [16,
18]. Incubation of blood with AN69 membrane fragments
resulted in severalfold higher bradykinin levels than when
incubated with Cuprophan membrane fragments [16, 18]. Sur-
prisingly, incubation longer than five minutes resulted in higher
bradykinin levels with Cuprophan, whereas with AN69 the
generated bradykinin disappeared [18]. With additional experi-
ments these findings could be explained by adsorption of
bradykinin to AN69 [18]. On the other hand, persisting gener-
ation of bradykinin is not expected during clinical dialysis with
Cuprophan as the early formation of a protein layer on the
membrane surface will block further activation of the Hageman
factor and therefore also the subsequent release of bradykinin.
The association of anaphylactoid reactions with hypochlorite
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(reprocessed but not with formaldehyde) reprocessed AN69
dialyzers [191 is in agreement with the hypothesis of surface
activation of the kallikrein-kinin pathway. Hypochlorite, a
strong oxidizing agent, removes the protein coat from AN69
and is therefore likely to activate the Hageman factor. In
contrast, the use of formaldehyde fixes the protein layer on the
surface and reduces the chance for further activation of the
Hageman factor. A recent report has associated anaphylactoid
reactions with reuse of hollow fiber hemodialyzers and ACE
inhibitors [20]. However, the relative contribution of the mem-
brane, the reuse procedure, or the reuse agent was not well
defined. On the other hand, our findings did not suggest any
association between the number of dialyzer uses and the risk of
developing an anaphylactoid reaction [6] (Table 1).
Practical experience shows that, generally, the amount of
bradykinin released within the dialyzer will not be enough to
exceed the threshold level necessary to trigger clinical reac-
tions. However, in particular cases, like the one reported above
or when bradykinin degradation is blocked by ACE inhibitors,
bradykinin may increase above a critical level to provoke
anaphylactoid reactions. Bönner et al, who have investigated
the vasodepressor effect of bradykinin in normotensive and
hypertensive subjects by injection of bradykinin intravenously
and intra-arterially, found a correlation between the increase in
arterial plasma levels of bradykinin and the corresponding fall
in systolic blood pressure [17]. Arterial bradykinin plasma
levels must increase approximately 250 fmollml in order to
achieve a drop in blood pressure of 50 mm Hg [17].
Although there is increasing evidence of the central pathoge-
netic role of the AN69 membrane in the induction of the
reported new type of anaphylactoid reaction, the unpredictabil-
ity of the occurrence of these reactions remains intriguing.
Despite combination of hemodialysis with AN69 and ACE
inhibition some patients do not develop anaphylactoid reactions
while others do so only episodically [6]. It is possible that this
is related to the dose and timing of the intake of the ACE
inhibitors in relationship to the start of the dialysis session. The
in vitro data provided by Lemke and Fink might support this
hypothesis [16]. The rinsing procedure of the dialyzer andlor
the anticoagulation mode might be invol ved with the contrib-
utory role of some dialysate factors: microbial contamination,
chemical composition and/or temperature. A central pathoge-
netic role of the microbial contamination of the dialysate in the
induction of anaphylactoid reactions during dialysis with AN69
membranes has been suggested [6,7]. However, anaphylactoid
reactions when using AN69 membranes have been described
during isolated ultrafiltration [19] and during hemofiltration [10],
and hemodiafiltration using sterile pyrogen-free fluids [21].
Secondly, our finding of a very low endotoxin content and
microbial count in the dialysis solution at the onset of several
episodes of anaphylactoid reactions equally argues against a
central pathogenetic role of a poor bacteriological quality of the
dialysis solution. However, these findings do not exclude that in
particular settings massive transfer of negatively-charged bac-
terial substances (such as endotoxins) from the dialysate to the
AN69 membranes might contribute to increased bradykinin
generation. It has been demonstrated in vitro that endotoxin
may activate the kallikrein-kinin pathway [22]. A recent report
documented the preventive role of alcalin rinsing of the AN69
dialyzers [23], suggesting that the negative charge of the mem-
brane may have been masked by adsorption of electrolytes on
the membrane resulting in a decreased activation of the kal-
likrein-kinin pathway.
In addition to these variable exogenous factors, interindivid-
ual differences in bradykinin generating and degrading capaci-
ties might play a role. Variable tissue and circulating bioactivity
of kallikrein inhibitors (Cl inhibitor, antithrombin III and
a-2-macroglobulin) may lead to differences in bradykinin gen-
eration. For instance, patients with hereditary angioedema
lacking Cl inhibitor have been shown to have an activated
kallikrein-kinin pathway during attacks of mucocutaneous
swellings [24]. On the other hand, interindividual differences in
degradation of bradykinin may exist. In addition to angiotensin
converting enzyme (kininase II), carboxypeptidase N (kininase
I) is an important enzyme for bradykinin degradation. Rare
genetic deficiencies in carboxypeptidase N have been reported,
and it is interesting to speculate that patients who are heterozy-
gous for carboxypeptidase N deficiency might be at greater risk
[25]. This hypothesis has also been put forward to explain why
only few non-dialysis patients (0.1%) treated with ACE inhibi-
tors develop angioedema [26]. On the other hand, patient
susceptibility might be related to the pathophysiological mech-
anism of vasodilation of bradykinin. Vasodilation is an indirect
effect of bradykinin, exerted by nitric oxide generated from
L-arginine by nitric oxide synthase [27]. The release of nitric
oxide might be decreased in the presence of hypercholesterol-
emia [28] and severe atherosclerosis [27]. Interestingly, accu-
mulation of asymmetric dimethylarginine, an endogeneous
competitive inhibitor of nitric oxide synthase, has been found in
the circulation of patients with chronic renal failure sufficient to
inhibit nitric oxide synthesis [29]. It is also conceivable that
some dialysis patients develop deficiency of L-arginine, which
is a small molecule easily dialyzed and found in high concen-
trations in fish, poultry and beans, the intake of which by
dialysis patients is restricted because of the high phosphorus
content. Therefore, it is tempting to speculate on the role of the
plasma levels of L-arginine and asymmetric dimethylarginine
on the patients' susceptibility to develop anaphylactoid reac-
tions.
In conclusion, our findings strongly suggest bradykinin to be
the mediator of the anaphylactoid reactions in patients dialyzed
with AN69 membranes. Of all dialysis membranes studied only
AN69 membranes provoked a significant generation of brady-
kinin. Simultaneous treatment with ACE inhibitors highly en-
hance the risk of development of anaphylactoid reactions by
reducing bradykinin breakdown. However, as we observed in
one patient dialyzed with AN69 membranes, anaphylactoid
reactions with high systemic bradykinin plasma levels can
develop even without treatment with ACE inhibitors. There-
fore, bradykinin generation must be regarded as a new marker
of biocompatibility.
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